The IL-2/IL-15 receptor systems: targets for immunotherapy.
about
Daclizumab therapy for multiple sclerosisReview of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosisInterleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumorsDaclizumab treatment for multiple sclerosis.Vaccines with enhanced costimulation maintain high avidity memory CTL.Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}Inhibition of immune activation by a novel nuclear factor-kappa B inhibitor in HTLV-I-associated neurologic disease.An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MSCombined stimulation of IL-2 and 4-1BB receptors augments the antitumor activity of E7 DNA vaccines by increasing Ag-specific CTL responses.Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.T cells expanded in presence of IL-15 exhibit increased antioxidant capacity and innate effector molecules.Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease.Novel antibodies as anticancer agents.Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review.Emerging therapies for multiple sclerosis.Effects of an agonist interleukin-2/Fc fusion protein, a mutant antagonist interleukin-15/Fc fusion protein, and sirolimus on cardiac allograft survival in non-human primates.Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple SclerosisSoluble interleukin-2 receptor α and interleukin-2 serum levels in patients with basal cell carcinomaBromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signalingModulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.Daclizumab for the treatment of multiple sclerosis.Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus.Interleukin (IL)-15 and IL-2 reciprocally regulate expression of the chemokine receptor CX3CR1 through selective NFAT1- and NFAT2-dependent mechanisms.IL-15 is decreased upon CsA and FK506 treatment of acute rejection following heart transplantation in mice.Spinal injection of IL-2 or IL-15 alters mechanical and thermal withdrawal thresholds in rats.Attenuation of rat chronic small bowel allograft rejection by n-3 polyunsaturated fatty acids is associated with reduced expression of graft IL-15.Vitamin D deficiency in early life accelerates Type 1 diabetes in non-obese diabetic mice.Interleukin-2, but not interleukin-15, is required to terminate experimentally induced clonal T-cell anergy.Effects of CD25 monoclonal antibody on proliferative and effector functions of alloactivated human T cells in vitro.Cholinergic neuron-like cells derived from bone marrow stromal cells induced by tricyclodecane-9-yl-xanthogenate promote functional recovery and neural protection after spinal cord injury.Daclizumab Therapy for Multiple Sclerosis.In vitro testing for anti-inflammatory properties of compounds employing peripheral blood mononuclear cells freshly isolated from healthy donors.Juxtacrine function of interleukin-15/interleukin-15 receptor system in tumour derived human B-cell lines.
P2860
Q27022517-A01DC382-067A-489C-B742-79453C28D7A2Q27693249-E6EBE90D-9627-4325-9A28-78379ADE96A8Q28296988-E42AE6E1-C935-488F-9869-D2455A46D7A7Q33382919-1A267D5E-715F-4977-A3E5-98540DBC42ACQ34312218-15080570-EE47-48D2-B46D-448BE4B43396Q34596171-49F4E771-A369-4749-9ACA-127A6A301FBCQ34694913-B960AC8F-65F7-4B95-82EC-CFF251A3D53CQ34754386-4DDA55A4-CC2D-430C-A78E-6CC937394870Q34893862-79497DCA-DA21-407B-B3C6-7D6C65817BEBQ35023350-FE7F24CD-4255-416F-BA65-B09432897431Q35082617-65499841-2E4A-4335-9629-98BB29D138DEQ35220386-6A84A31C-600B-42DC-8B44-A2BF38CC33F6Q36678607-77944242-753A-4D24-B54C-9D9DF16C0B4CQ36708311-800685AA-743D-4167-A8ED-AD680A860A8FQ36832141-0F7E1F06-D2C2-41BF-B949-81CFDEF0D0D7Q36956380-D03647AB-16D3-4956-8BE1-CD75D750F72FQ36963208-8AB2E665-9BC2-4EA3-8AD1-BBCFB017B3E7Q37063449-A9B4AF16-93E0-43E0-8D19-A8770EB068A8Q37080630-33984C33-BB2A-4342-929E-74928C76834AQ37215888-1107CE38-A6EE-460B-8D84-1A69F1DBC695Q37388856-77A05FBE-8FF8-4E84-B75A-C967F7A3F5D4Q38111620-00DB8258-68E8-45FA-A2FA-2FCAA06DCDFAQ38604207-C1107F2F-C862-4C96-8C19-2B3DCD4E7E0FQ40479713-CB9DCC9B-B7E0-414B-BBD7-071EE8BBEFF4Q40519217-1269F611-26E8-43A7-B6F4-3E0FFF5B6D52Q43012897-617B4317-3550-4E50-A7B7-B11C5119A88BQ43104975-7757389B-BE22-4801-AA11-883E589D2AB7Q44297966-154DD407-EF1C-44B4-8369-6A91B7E83BD5Q44752917-E9CB5FA5-51C3-4BA1-96BC-D9FFD177AFF6Q47239357-B7CB8A62-A6B0-404E-98E9-856BCC710F88Q48020696-1AFD3BE5-95B0-4C62-81D6-FD5B820E1026Q50782088-01A9F731-D05B-4EFA-8C81-168AF5E17DF1Q52319805-D17A9B2F-A267-4F0E-86C6-F026A28998E7Q53304078-EE162391-182D-45C5-871A-05E409E5E2EFQ54571746-98E592EC-038A-44ED-94C4-566FF7FAD188
P2860
The IL-2/IL-15 receptor systems: targets for immunotherapy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The IL-2/IL-15 receptor systems: targets for immunotherapy.
@ast
The IL-2/IL-15 receptor systems: targets for immunotherapy.
@en
The IL-2/IL-15 receptor systems: targets for immunotherapy.
@nl
type
label
The IL-2/IL-15 receptor systems: targets for immunotherapy.
@ast
The IL-2/IL-15 receptor systems: targets for immunotherapy.
@en
The IL-2/IL-15 receptor systems: targets for immunotherapy.
@nl
prefLabel
The IL-2/IL-15 receptor systems: targets for immunotherapy.
@ast
The IL-2/IL-15 receptor systems: targets for immunotherapy.
@en
The IL-2/IL-15 receptor systems: targets for immunotherapy.
@nl
P356
P1476
The IL-2/IL-15 receptor systems: targets for immunotherapy.
@en
P2093
Thomas A Waldmann
P2888
P356
10.1023/A:1014416616687
P577
2002-03-01T00:00:00Z
P6179
1019962711